crizotinib and Intestinal-Perforation

An 86-year-old Japanese man was diagnosed with stage IV lung adenocarcinoma. The patient was treated with crizotinib after echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement was detected from his pleural effusion. He subsequently developed abdominal pain and rebound tenderness in the right lower abdomen. Contrast-enhanced abdominal CT showed a low-density area in the abdominal cavity. The size of the abscess was decreased by drainage and the administration of antibiotics. Fistulography revealed a fistula from the rectum to the abscess, and a diagnosis of lower intestinal tract perforation with abscess formation was made. Crizotinib was discontinued and treatment with alectinib was initiated. The patient remains under treatment as an outpatient at our department without adverse effects.

Topics: Abscess; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fistula; Humans; Intestinal Perforation; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Rectum; Treatment Outcome